The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...

Galderma has shared positive two-year data for its monoclonal antibody Nemluvio (nemolizumab) in moderate-to-severe atopic ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved ...

Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the saf ...

New interim two-year data from a long-term extension study of Nemluvioin atopic dermatitis reinforce its rapid onset of action and demonstrate its ...

Conversations in Dermatology: 2025 will focus on clinical challenges and recent advances that health care providers who manage chronic pruritic conditions should know.

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

In our JAK inhibitors session at the AAD, I discussed the role of JAK inhibitors in atopic dermatitis, prurigo nodularis, and also pruritus, or itch in general. For topical agents, we focused on ...

Ruxolitinib cream is effective for atopic dermatitis and prurigo nodularis, with low adverse event rates in long-term use. The cream reduces the need for other topical treatments and biologics in ...

Nemolizumab “is also the first and only biologic approved for atopic dermatitis and prurigo nodularis with 4-week dosing intervals from the start of treatment,” according to the statement.